baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Discount Zert SNW 3.../ DE000SV7QPJ2 /

10/06/2024 15:14:24	Chg.-0.580	Bid15:46:48	Ask15:46:48	Underlying	Strike price	Expiration date	Option type
89.870EUR	-0.64%	89.830 Bid Size: 3,000	89.930 Ask Size: 3,000	SANOFI SA INHABER ...	- EUR	31/12/2024	Call

GlobeNewswire 14:00 MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for...

GlobeNewswire 03/06 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...

GlobeNewswire 31/05 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

GlobeNewswire 31/05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 31/05 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewswire 31/05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 31/05 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...

GlobeNewswire 30/05 Press Release: Sanofi completes acquisition of Inhibrx, Inc.

GlobeNewswire 27/05 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...

GlobeNewswire 23/05 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

GlobeNewswire 21/05 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 20/05 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 20/05 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...

GlobeNewswire 13/05 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...

GlobeNewswire 13/05 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

TeleTrader 13/05 Europe mixed at open as CPI prints loom

GlobeNewswire 13/05 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

TeleTrader 10/05 Novavax skyrockets 213.5% in premarket, highest in 16 months

TeleTrader 10/05 Novavax soars 39.6% in premarket after Sanofi license deal

GlobeNewswire 10/05 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...

GlobeNewswire 09/05 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

TeleTrader 09/05 Europe opens mixed with BoE in focus

GlobeNewswire 08/05 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 07/05 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Soc. Generale Discount Zert SNW 3.../ DE000SV7QPJ2 /

If you wish to receive reply to your feedback, please provide your email address.